Health
Oncology Landmark vs. Financial Selloff | Why Oncologists Praise Moderna and Merck’s Cancer Vaccine While Wall Street Dumps Shares
Moderna and Merck’s personalized mRNA cancer vaccine cut melanoma recurrence or death by 42% in late-stage data. While clinical oncologists celebrate a historic turning point in personalized oncology, an equity selloff reveals a sharp disconnect between medical reality and market expectations.
Camila Henry • Oct 23, 2026 • 4m read